Publications found:
241
Sort by:
Precision Psychiatry Market Size, Share & Trends Analysis Report By Service Type (Genetic Testing, Biomarker Analysis), By Technology (Immunoassay, Polymerase Chain Reaction), By Therapeutic Area (Hospitals & Clinics, Clinical Laboratories), By End-user, By Region, And Segment Forecasts, 2025 - 2033
US$ 5,950.00
Precision Psychiatry Market The global precision psychiatry market size was estimated at USD 825.6 million in 2024 and is projected to reach USD 2,858.0 million by 2033, growing at a CAGR of 14.91% fr...
September 2025
120 pages
ADHD Focus Wearables Market Forecasts to 2032 – Global Analysis By Product (Smartwatches, Headbands & Neurofeedback Devices, Smart Glasses, Wearable Sensors and Other Products), Distribution Channel, Technology, Application, End User and By Geography
US$ 4,150.00
According to Stratistics MRC, the Global ADHD Focus Wearables Market is accounted for $737.9 million in 2025 and is expected to reach $2,110.7 million by 2032 growing at a CAGR of 16.2% during the for...
September 2025
200 pages
Alzheimer's Drugs Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class [Cholinesterase Inhibitors (Donepezil, Rivastigmine, and Galantamine) NMDA Receptor Antagonists, Combination Drugs, and Others] and End User (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
US$ 4,450.00
The Alzheimer's drugs market size is expected to grow from US$ 8.24 billion in 2024 to US$ 26.37 billion by 2031; it is projected to register a CAGR of 13.6% during 2025-2031. The aging population & r...
August 2025
215 pages
Multiple Sclerosis Therapies Market Report by Drug (Immunomodulators, Immunosuppressants), Drug Type (Biologic Drugs, Small Molecule Drugs), Route of Administration (Oral, Injectable, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2025-2033
US$ 3,999.00
The global multiple sclerosis therapies market size reached USD 27.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 38.8 Billion by 2033, exhibiting a growth rate (CAGR)...
August 2025
120 pages
Neurodegenerative Disease Treatment Market Report by Indication (Multiple Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, Spinal Muscular Atrophy (SMA), Huntington’s Disease, and Others), Drug Type (N-Methyl-D-Aspartate Receptor Antagonists, Selective Serotonin Reuptake Inhibitors, Dopamine Inhibitors, and Others), Route of Administration (Oral, Injectable, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region 2025-2033
US$ 3,999.00
The global neurodegenerative disease treatment market size reached USD 78.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 118.5 Billion by 2033, exhibiting a growth rat...
August 2025
124 pages
Anti-Parkinson’s Drugs: Global Markets to 2030
US$ 4,650.00
... global market for anti-Parkinson’s drugs and their future demand Analyses of global market trends, with ... printed drugs, mobile applications and wearable technologies in the monitoring and treatment of Parkinson’s disease Discussion of the major segments of the anti-Parkinson’s drugs, i.e., dopaminergic drugs ...
July 2025
134 pages
Cognitive and Memory Enhancer Drugs Market Report by Product (Aricept, Exelon, Namenda, Razadyne, Provigil, Ritalin, Adderall, and Others), Application (Disease Treatment, Athletic Performance, Academic Performance, and Others), and Region 2025-2033
US$ 3,999.00
The global cognitive and memory enhancer drugs market size reached USD 6,171.6 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 9,460.6 Million by 2033, exhibiting a growt...
March 2025
139 pages
Depression Drugs Market Report by Drug Class (Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Selective Serotonin Reuptake Inhibitors (SSRIs), Central Nervous System (CNS) Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Others), Disorder Type (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others), Drug Type (Generic Drugs, Branded Drugs), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Region 2025-2033
US$ 3,999.00
The global depression drugs market size reached USD 19.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 25.1 Billion by 2033, exhibiting a growth rate (CAGR) of 2.9% dur...
March 2025
148 pages
Neuropathic Pain Market Forecasts to 2030 – Global Analysis By Drug Class (Antidepressants, Anticonvulsant, Opioids, Capsaicin, Steroids and Other Drug Classes), Indication, Patient Type, Route of Administration, Distribution Channel and By Geography
US$ 4,150.00
According to Stratistics MRC, the Global Neuropathic Pain Market is accounted for $8.24 billion in 2024 and is expected to reach $14.35 billion by 2030 growing at a CAGR of 9.7% during the forecast pe...
February 2025
150 pages
Opioid Use Disorder (OUD) Market Size, Share, and Analysis, By Drug Class (Buprenorphine, Methadone, and Naltrexone), By Route of Administration (Oral, Sublingual, and Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034
US$ 4,950.00
Opioid Use Disorder (OUD) Market Size, Share, and Analysis, By Drug Class (Buprenorphine, Methadone, and Naltrexone), By Route of Administration (Oral, Sublingual, and Intravenous), By Distribution Ch...
October 2024
473 pages
Pregabalin Market By Type (Tablets and Capsules, Others), By Application (Epilepsy, Neuropathic Pain, Others), By Distribution Channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2022 - 2032
US$ 3,570.00
The pregabalin market was valued at $1.6 billion in 2022 and is estimated to reach $2.2 billion by 2032, exhibiting a CAGR of 3% from 2023 to 2032. Pregabalin belongs to a group of drugs known as anti...
February 2024
289 pages